|
|
| Titles |
1993 AJP Buspar |
| Related Item |
|
| Genre |
medicine |
| Identifier |
AMJP1993Jan_Mar(Page 10).png |
| Note |
Because approximately 60% of patients with persistent anxiety may exhibit depressive symptoms…BuSpar 10mg (buspirone HCl) Now indicated for the relief of persistent anxiety coexisting depressive symptoms. Anxiolytic efficacy demonstrated in anxious patients with or without coexisting depressive symptoms. Relief of anxiety symptoms begins within 1 week, progresses steadily through the fourth week of therapy. Nonaddictive, no more sedation (10%) than seen with placebo (9%). The more commonly observed untoward events include dizziness (12%), nausea (8%), headache (6%), and nervousness (5%). Progressive relief of persistent anxiety. BuSpar is not indicated for the relief of primary depressive disorder. |
| Abstract |
Buspirone HCl, Bristol-Myers Squibb Company, Three female closeups, two of which of holding their head with their hand; the third is holding her chest. All have a negative expression on their face. Seems to be missing a page. Could be useful for specificity/biomedicine, as it now lists it can help anxiety with depression, but not primary depression alone. |